Wilms' tumour gene 1 (WT1) in human neoplasia

被引:72
作者
Keilholz, U
Menssen, HD
Gaiger, A
Menke, A
Oji, Y
Oka, Y
Scheibenbogen, C
Stauss, H
Thiel, E
Sugiyama, H
机构
[1] Charite, Dept Med 111, D-12200 Berlin, Germany
[2] Schering AG, Med Dev Oncol US, Berlin, Germany
[3] Univ Vienna, Dept Hematol & Oncol, Vienna, Austria
[4] Univ Med Ctr St Radboud Nijmegen, Nijmegen, Netherlands
[5] Osaka Univ, Grad Sch Med, Dept Mol Med, Osaka, Japan
[6] Hammersmith Hosp, Dept Immunol, London, England
关键词
WT1; meeting; monitoring; vaccination; minimal residual disease;
D O I
10.1038/sj.leu.2403817
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transcription factor Wilms' tumour gene 1 (WT1) is important as a prognostic marker as well as in the detection and monitoring of minimal residual disease in leukaemia and myelodysplastic syndromes. Evidence has accumulated over the past decade to show that WT1 is a key molecule for tumour proliferation in a large number of human neoplasms most prominent in acute leukaemias, making it a suitable target for therapeutic strategies. Based on animal results, showing safety and efficacy of immunization with WT1 peptides and protein, early clinical trials in leukaemia have recently been initiated. The First International Conference on WT1 in Human Neoplasia was held in Berlin, March 11-12, 2004. This report reviews the current knowledge on the role of WT1 in tumour promotion and as a diagnostic and therapeutic target, and summarizes the data presented and discussed in this meeting.
引用
收藏
页码:1318 / 1323
页数:6
相关论文
共 50 条
  • [1] Algar EM, 1996, ONCOGENE, V12, P1005
  • [2] Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes
    Azuma, T
    Otsuki, T
    Kuzushima, K
    Froelich, CJ
    Fujita, S
    Yasukawa, M
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7402 - 7412
  • [3] Baird PN, 1997, EXP HEMATOL, V25, P312
  • [4] Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes
    Bendle, GM
    Holler, A
    Pang, LK
    Hsu, S
    Krampera, M
    Simpson, E
    Stauss, HJ
    [J]. CANCER RESEARCH, 2004, 64 (21) : 8052 - 8056
  • [5] ISOLATION AND CHARACTERIZATION OF A ZINC FINGER POLYPEPTIDE GENE AT THE HUMAN CHROMOSOME-11 WILMS TUMOR LOCUS
    CALL, KM
    GLASER, T
    ITO, CY
    BUCKLER, AJ
    PELLETIER, J
    HABER, DA
    ROSE, EA
    KRAL, A
    YEGER, H
    LEWIS, WH
    JONES, C
    HOUSMAN, DE
    [J]. CELL, 1990, 60 (03) : 509 - 520
  • [6] WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome
    Cilloni, D
    Saglio, G
    [J]. ACTA HAEMATOLOGICA, 2004, 112 (1-2) : 79 - 84
  • [7] Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes
    Cilloni, D
    Gottardi, E
    Messa, F
    Fava, M
    Scaravaglio, P
    Bertini, M
    Girotto, M
    Marinone, C
    Ferrero, D
    Gallamini, A
    Levis, A
    Saglio, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) : 1988 - 1995
  • [8] Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients
    Cilloni, D
    Gottardi, E
    De Micheli, D
    Serra, A
    Volpe, G
    Messa, F
    Rege-Cambrin, G
    Guerrasio, A
    Divona, M
    Lo Coco, F
    Saglio, G
    [J]. LEUKEMIA, 2002, 16 (10) : 2115 - 2121
  • [9] Dehbi M, 1996, ONCOGENE, V13, P447
  • [10] PAX8-mediated activation of the wt1 tumor suppressor gene
    Dehbi, M
    Pelletier, J
    [J]. EMBO JOURNAL, 1996, 15 (16) : 4297 - 4306